Yale School of Medicine (YSM) researchers have tested a new and potentially more sensitive neuroimaging tool for diagnosing ...

Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC). Background: The role of F-18 FDG-PET/CT ...

Reston, VA—A new radiotracer, 68 Ga-FAP-2286, has been found to be more effective than the most commonly used nuclear medicine cancer imaging radiotracer, 18 F-FDG. In a study published in the March ...

FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.

Visual Abstract. Comparison of FDG PET 3D-SSP z score maps and transaxial slices of the temporal lobe, along with corresponding MRI images, among individuals suspected of having Alzheimer's disease ...

Clinical benefit and quality of life in patients with advanced biliary tract cancer receiving gemcitabine plus capecitabine (GemCap): Results from a multicenter phase II trial (SAKK 44/02) No ...

[18 F]FDG (2-[18 F]fluoro-2-deoxy-D-glucose) is the most widely utilized radiotracer in positron emission tomography (PET). Its imaging capabilities are based on the Warburg effect, which describes ...